We are live on ! Find out more
AWGLSCP

ABG-WTT Global Life Science Capital Partners Portfolio holdings

AUM $12.3M
1-Year Est. Return 3.13%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
–
AUM
$41.5M
AUM Growth
-$9.79M
Cap. Flow
-$12.4M
Cap. Flow %
-29.83%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$37.4M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$48.4M
2
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.66B
$40.2M 96.81%
+915,501
New +$37.4M
RPID icon
2
Rapid Micro Biosystems
RPID
$87.2M
$768K 1.85%
1,038,296
– –
LUNG icon
3
Pulmonx
LUNG
$94.1M
$558K 1.34%
60,204
– –
RYZB
4
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-778,922
Closed -$48.4M
MDVL
5
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
– –
-300,588
Closed -$1.35M

Similar funds

M
MetLife New York $12.3M AUM 29% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $12M AUM 8.79% 1-Year Est. Return
VH
Vitol Holding Rotterdam, Netherlands $11.9M AUM 27.28% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
CCM
Crabel Capital Management Los Angeles, California $10.8M AUM 3.34% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's Q1 2024 Portfolio in Review

As of Q1 2024, ABG-WTT Global Life Science Capital Partners held 5 positions worth $41.5M, down 19% from $51.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG-WTT Global Life Science Capital Partners withdrew a net $12.4M in Q1 2024, closing 2 positions. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $48.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, ABG-WTT Global Life Science Capital Partners opened a new position in CG Oncology worth $40.2M.

  • ABG-WTT Global Life Science Capital Partners's largest Q1 2024 buy was CG Oncology: 915,501 shares worth $40.2M.
  • ABG-WTT Global Life Science Capital Partners fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $48.4M.
  • ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $41.5M portfolio in Q1 2024.
  • ABG-WTT Global Life Science Capital Partners opened 1 new position and closed 2 in Q1 2024.
  • ABG-WTT Global Life Science Capital Partners's portfolio value fell 19% quarter-over-quarter to $41.5M.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.